Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UCBSTU:UNC -1.60%90 Debt-to-Equity is 0.31 as of Jun. 2026, which is 7% above its 10-year median of 0.29. GuruFocus rates STU:UNC with a GF Score™ of 90/100 and a GF Value™ of €251.55 (Modestly Undervalued). Among 956 Biotechnology companies, UCB ranks worse than 64.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for UCB's Debt-to-Equity or its related term are showing as below:
STU:UNC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18 Med: 0.29 Max: 0.41
Current: 0.31
During the past 13 years, the highest Debt-to-Equity Ratio of UCB was 0.41. The lowest was 0.18. And the median was 0.29.
STU:UNC's Debt-to-Equity is ranked worse than 64.44% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs STU:UNC: 0.31
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
UCB Debt-to-Equity Related Terms
UCB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for UCB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:UNC vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, UCB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where UCB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (STU:UNC) has a Debt-to-Equity of 0.31 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on UCB and its competitors. This is near median its historical median of 0.29. Over the past decade, UCB's Debt-to-Equity has ranged from 0.18 to 0.41. According to the industry distribution chart, UCB ranks #616 out of 956 companies in the Biotechnology industry, placing it in the top 64.4%.
Is UCB's Debt-to-Equity too high?
UCB's current Debt-to-Equity of 0.31 is near median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 0.41. The Biotechnology industry median Debt-to-Equity is 0.16. UCB's value of 0.31 is 93.8% above this industry median. Based on the distribution chart, UCB ranks #616 out of 956 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UCB has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #616 out of 956 companies for Debt-to-Equity. This places UCB in the lower half of its industry. The industry median Debt-to-Equity is 0.16. UCB's value of 0.31 is 93.8% above this benchmark. Historically, UCB's own Debt-to-Equity has ranged from 0.18 to 0.41 over the past decade. While the company's 10-year median is 0.29 vs. the industry median of 0.16, UCB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current Debt-to-Equity of 0.31 is 93.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on UCB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current Debt-to-Equity is 0.31, which is near median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Undervalued. The stock's GF Value™ is €251.55, compared to a current price of €220.70 — trading 12.3% below its estimated fair value. The current Debt-to-Equity is 0.31, which is near median its 10-year median of 0.29 and 93.8% above the Biotechnology industry median of 0.16. UCB's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For UCB (STU:UNC), the current Debt-to-Equity is 0.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (STU:UNC) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be undervalued.
The current stock price of €220.70 is trading 12.3% below its estimated GF Value™ of €251.55.
GuruFocus considers UCB to be Modestly Undervalued.
Key valuation signals for STU:UNC:
Debt-to-Equity: 0.31 (near median its 10-year median of 0.29)
GF Value™: €251.55 vs. price of €220.70 (12.3% below fair value)
Industry Position: 93.8% above the Biotechnology median (#616 of 956)
No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score
Get the complete analysis for STU:UNC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNC has been successfully added to your 
